IsoPlexis eBook - 16

I S O P L E X I S ' U N I Q U E , P R E D I C T I V E B I O LO G Y

Overcoming the Limitations of Genomics
Using Single-Cell Proteomics

A

s mentioned earlier, GBM is a highly lethal

by single-cell proteomics and metabolomics was

cancer that mutates quickly, but rather

successful and led researchers to understand that

than a single genetic alteration, the

the two pathways they identified are independently

genomic analyses show that most tumors are driven

druggable.2

by derangements in multiple intracellular pathways.

Cancer is best addressed as a multi-dimensional

Writing in a Cancer Cell commentary, Lam and

disease beyond the initial confines of genetic pertur-

Yaffe said that this panoply of genomic alterations

bations that drive oncogenesis. Understanding how

enhances the tumor's ability to rapidly and dynam-

different systems behave within a tumor can lead to

ically rewire its signaling circuitry and to reactivate

novel therapeutic combinations that demonstrate

key regulatory nodes following treatment with single

temporal synergy by intentionally targeting dynamic

pathway blocking agents, leading to therapeutic

rewiring of signaling pathways to increase sensitivity

resistance.1

rather than drive resistance.

The authors stress that there is a likelihood to
miss this rewiring if genomics is the sole single-cell
analysis and indicate a need to break the current
"glass ceiling" of solely relying on genomic dataset
analyses to advance cancer therapeutics. They
emphatically point out that intracellular signaling
networks, or functional proteomics, need to be
investigated further in order to provide insight into
how to combat adaptive resistance.

Understanding how different systems
behave within a tumor can lead to
novel therapeutic combinations
that demonstrate temporal
synergy by intentionally targeting
dynamic rewiring of signaling
pathways to increase sensitivity
rather than drive resistance.

This is evident in the previous section, discussing
the case by Su et al., where IsoPlexis' Single-Cell Intra-

Again, IsoPlexis' unique single-cell proteomics

cellular Proteomics and Metabolomics were essential

technology was key to this discovery. Researchers

in identifying how cells progress from drug-tolerant

Wei et al. used the information they learned

to drug-resistant. Identifying this allowed researchers

from running single-cell analyses to test several

to test combinatorial therapies to prevent this

combination therapies against tumor growth. The

resistance. The combination therapy predicted

combination therapies predicted by single-cell

16 |

GENengnews.com



http://www.GENengnews.com

IsoPlexis eBook

Table of Contents for the Digital Edition of IsoPlexis eBook

Contents
IsoPlexis eBook - 1
IsoPlexis eBook - 2
IsoPlexis eBook - Contents
IsoPlexis eBook - 4
IsoPlexis eBook - 5
IsoPlexis eBook - 6
IsoPlexis eBook - 7
IsoPlexis eBook - 8
IsoPlexis eBook - 9
IsoPlexis eBook - 10
IsoPlexis eBook - 11
IsoPlexis eBook - 12
IsoPlexis eBook - 13
IsoPlexis eBook - 14
IsoPlexis eBook - 15
IsoPlexis eBook - 16
IsoPlexis eBook - 17
IsoPlexis eBook - 18
https://www.nxtbookmedia.com